Latest ArticlesTo investigate the susceptible factors of liver injury after chemotherapy with R-CHOP (rituximab+cyclophosphamide+doxorubicin hydrochloride liposome injection+oncovin+prednisone) in non-Hodgkin lymphoma (NHL) patients, and to observe the hepatoprotective effect of prophylactic magnesium isocyanate.
The clinical data of 328 NHL patients who met the diagnostic criteria were collected and analyzed from January 1, 2016 to December 31, 2021 in the Department of Hematology, Shidong Hospital, Yangpu District, Shanghai. According to whether hepatoprotective treatment was used in chemotherapy, the patients were divided into two groups according to whether or not hepatoprotective treatment. First, the liver injury patients were determined in the group of unprotected liver patients, and the susceptible factors for liver injury after R-CHOP chemotherapy were analyzed. Then all patients were divided into four groups: non-susceptible factors without liver protection group (A group), susceptible factors without liver protection group (B group), non-susceptible factors with liver protection group (C group), susceptible factor with liver protection group (D group). Groups C and D were treated with magnesium isoglycyrrhizinate for liver protection. The incidence of liver injury and the changes of liver function indexes alanine aminotransferase (ALT), alkaline phosphatase (ALP) and (total bilirubin, TBiL)] of all patients before and after chemotherapy were compared and statistically analyzed.
Alcohol consumption, non-alcoholic fatty liver disease, HBV carriers, and lymphoma liver infiltration were found to be independent susceptible factors for liver injury in NHL patients after R-CHOP chemotherapy. There was no significant difference in the incidence of liver injury (8.13%/5.48%) among the patients without susceptibility factors, while in the patients with susceptibility factors, the incidence of liver injury in the liver protection patients was significantly reduced (7.55%/40.51%). The levels of ALT, ALP and TBiL in patients with susceptibility factors were higher than those without susceptibility factors, and the differences were statistically significant (P<0.05).
Alcohol consumption, non-alcoholic fatty liver disease, HBV carriers and liver infiltration of lymphoma are independent susceptible factors for liver injury in NHL patients after R-CHOP chemotherapy. For NHL patients with the above susceptible factors, magnesium isoglycyrrhizinate can be used to protect the liver effectively during R-CHOP chemotherapy.
Vertigo and sudden deafness are common in clinic and have great impact on patients' life. Pentoxifylline is a non selective phosphodiesterase inhibitor, which can increase cyclic adenosine monophosphate in vertebral basilar artery and inner ear circulation cells, inhibit atherosclerosis and inflammation and improve hemorheology. Pentoxifylline may be used to treat vertigo and sudden deafness. This article reviewed the relevant research progress in order to provide reference for clinical practice.
To investigate the use of antimicrobial agents and its influencing factors among parents of pediatric children, so as to provide evidence for better education on rational use of antibiotics.
A self-designed questionnaire was used to investigate the demographic characteristics of the parents of the children and the specific antimicrobial agents use behavior before, during and after the visit. Chi-square test was used for univariate analysis to determine the demographic factors of irrational antimicrobial agents use. Logistic regression analysis was used for multivariate analysis to determine how demographic factors affect the use of antibiotics.
Before treatment, 20.8% of the parents had irrational antimicrobial agents use behavior, and the decision makers of antimicrobial agents use were the influencing factors of antimicrobial use behavior. The parents with irrational drug use behaviors accounted for 11.2%, and the family monthly income was the influencing factor of the parents' antimicrobial drug use behaviors. After treatment, 19.2% of the parents had irrational drug use. Medical insurance and reimbursement of outpatient expenses were the influencing factors of parents' antimicrobial agents use behavior.
The hospital is the main place for children's families to obtain the knowledge of antibacterial drugs. Therefore, it is very important for doctors to strengthen the propaganda and education of key contents such as abuse, random drug withdrawal, drug reduction and preparation of drugs for key groups during their visits, and to strengthen the propaganda and education of the relationship between diseases and antibacterial drugs, the hazards of abuse of antibacterial drugs, precautions for the use of antibacterial drugs, and antimicrobial drug resistance.
Chinese herbal injections for clearing heat and invigorating blood should be used rationally under the guidance of traditional Chinese medicine theory and in accordance with the principles of evidence-based treatment, which is widely used in combination with antimicrobial agents in clinical practice. And it is commonly used for the treatment of patients in acute and critical conditions. The combination of antimicrobial agents is particularly effective in the treatment of serious infections. This article reviewed the clinical application of heat-clearing and blood-activating herbal injections combined with antimicrobial agents in the treatment of serious infections, explained the current status of research on the combination of heat-clearing and blood-activating herbal injections with antimicrobial agents in the treatment of serious infections such as sepsis, severe pneumonia. To summarize the effects such as clinical efficacy and contraindications of combining heat-clearing and blood-activating herbal injections with antimicrobial agents, and to facilitate the safe and effective use of herbal injections in clinical practice. It also provided a theoretical basis and reference for an in-depth discussion on the clinical application of heat-clearing and blood-activating herbal injections in combination with antimicrobial agents.
Bacterial drug resistance is one of the hot spots in the 21st century. At least 700 000 people die from drug-resistant bacteria causing diseases every year, and drug resistance has created a huge economic and health burden. In recent years, in order to delay the process of bacterial drug resistance, under the guidance and promotion of government policies, the scientific community and the academic community have made joint efforts. At present, a variety of new antimicrobial agents have been developed in different stages of research or have been marketed. This present article briefly reviewed the drugs that had been marketed and are in phase Ⅲ clinical studies in recent years, and mainly used for the treatment of drug-resistant bacterial infections and new non-traditional antimicrobial agent substitutes. In order to provide reference for related research and clinical application, the relevant pharmacology, clinical studies and safety of the drug were introduced.
Tuberculosis is the most common opportunistic infection in acquired immune deficiency syndrome (AIDS) patients. The treatment for AIDS patients with tuberculosis is more complicated than the tuberculosis patients without AIDS, and the success rate of treatment is not ideal. Many factors, including medication compliance, adverse drug reactions and drug interactions, will affect the treatment effect of AIDS patients with tuberculosis. This article reviewed the latest advances in the treatment of AIDS patients with tuberculosis, and briefly discussed the interaction between anti-viral and antitubercular drugs and the adverse drug reactions of coadministration, so as to provide a reference for clinical treatment.
To study the effects of micro RNA (miR)-181b on lipopolysaccharide (LPS)-induced pancreatic islet β cells proliferation, apoptosis, insulin secretion level and activation of nuclear factor (NF)-κB signaling pathway and its mechanism.
Islet β cells from MIN6 mice were randomly divided into control group, LPS group, anti-miR-NC+LPS group (transfection inhibitor control), anti-miR-181b+LPS group (transfection miR-181b inhibitor) and anti-miR-181b+NF-κB signal activator pathway phorbol myristate acetate (PMA)+LPS group (transfection miR-181b inhibitor+PMA). The cell proliferation, apoptosis, insulin secretion and the protein expression of B cell lymphoma/leukemia (Bcl)-2 protein, Bcl-2 related X protein (Bax) and NF-κB p65 were measured, respectively.
Compared with the control group, the levels of miR-181b, apoptosis rate, protein expression of Bax and NF-κB p65 in the LPS group were increased, while cell proliferation activity, Bcl-2 protein expression and insulin secretion were decreased (P<0.01). Compared with the LPS group, the level of miR-181b, apoptosis rate, Bax and NF-κB p65 protein expression in the anti-miR-181b+LPS group were decreased (P<0.01), while the cell proliferation activity, Bcl-2 protein expression and insulin secretion were slightly increased, but there was no significant differences (P>0.01). PMA could slightly reverse the effects of down-regulation of miR-181b on the proliferation, apoptosis and insulin secretion of pancreatic β cells induced by LPS, but the reverse effect was not significant.
Downregulation of miR-181b can significantly inhibit the apoptosis of islet β cells induced by LPS, but has no significant effects on their proliferation and insulin secretion, which may be related to the inhibition of NF-κB signaling.
To investigate the effects of Shaoxianyu granules on liver and spleen tissue damage and helper T cell (Th)17/regulatory T cell (Treg) immune balance in mice with immune thrombocytopenia (ITP).
Thirty C57BL/6 mice were randomly divided into control group, model group, Shaoxianyu granules low-dose group (5.85 g/kg), high-dose group (11.7 g/kg) and prednisone group (5.4 mg/kg), 6 mice in each group. The immune-related indicators, Th17 and Treg cells in each group were detected, the Th17/Treg ratio was calculated, and the morphological changes of the liver and spleen were observed.
Compared with the control group, the platelet count decreased in the model group, and the concentration of platelet-related immunoglobulin (PAIg) increased (P<0.05). Compared with the control group, the platelet count increased and the concentration of PAIg decreased in Shaoxianyu granules low-dose and high-dose groups (P<0.05). Compared with the control group, the contents of interleukin (IL)-17 and transforming growth factor (TGF)-β1 decreased in the model group, and the content of IL-10 increased (P<0.05), while the content of IL-17 and TGF-β1 increased, and the content of IL-10 decreased in Shaoxianyu granules low-dose and high-dose groups (P<0.05). Compared with the control group, the spleen tissue of the mice in the model group was disordered, the white pulp was larger, the red pulp was smaller, a large number of abnormally developed megakaryocytes were seen in the medullary cord and sinus, the liver tissue was swollen, the hepatic lobule structure disappeared, and a large number of inflammatory cells infiltrated in the portal area and the interstitium. Compared with the model group, the pathological changes of the liver and spleen in Shaoxianyu granules low and high dose groups were significantly improved, and the curative effect was equivalent to that of the prednisone group. Compared with the control group, the number of Th17 cells in the model group increased, while the number of Treg cells decreased, and the ratio of Th17/Treg increased (P<0.05). Compared with the control group, the ratios of Th17/Treg in Shaoxianyu granules low and high-dose groups decreased correspondingly (P<0.05).
Shaoxianyu granules can significantly increase the number of platelets in ITP mice, effectively control bleeding, and protect the spleen and liver tissues of ITP mice by regulating the immune balance of Th17/Treg cells.
To explore the potential mechanism of Rhizoma Cimicifugae on dermatomyositis and polymyositis by using network pharmacology and molecular docking technology.
The components and action targets of Rhizoma Cimicifugae were screened out by using the systematic pharmacology database and analysis platform of traditional Chinese medicine system. The disease genes were obtained from Genecards and Drugbank databases with "dermatomyositis" and "polymyositis" as disease keywords. Venny 2.1 was used to obtain the intersection targets, Cytoscape 3.7.1 software was used to construct the component-disease-target map, and the STRING database was used to construct protein-protein interaction network. R software was used for analysis, Gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the acting targets. Autoduck and Pymol software were used for molecular docking and visual display.
Nine active components, 60 targets, 1 247 disease targets, 13 intersection targets, 68 biological processes enriched by GO, 11 cell compositions, 23 molecular functions, and 61 KEGG enrichment pathways were obtained (P<0.05). The results of molecular docking indicated that the four active ingredients had good binding ability to the core target.
The active components of cimicic acid, deoxycimicidal hydrocarbon and stigmasterol may act on interleukin-6, tumor necrosis factor, prostaglandin endoperoxidase 2 and peroxisome proliferator activated receptors γ. It regulates the inflammation and immune response of myositis through interleukin-17, toll like receptor and retinoic acid-induced gene Ⅰ.
To analyze the efficacy and safety of icotinib hydrochloride combined with intensity-modulated radiation therapy (IMRT) in the treatment of brain metastases from epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma.
One-hundred cases of brain metastases patients from EGFR mutation-positive lung adenocarcinoma admitted to the first affiliated hospital of Henan university from April 2017 to April 2019 were retrospectively analyzed, and they were divided into the targeted therapy group (n=50) and the combined therapy group (n=50) according to the treatment method. The targeted therapy group were treated with icotinib hydrochloride, and the combined therapy group received IMRT treatment on the basis of the targeted therapy group. After four months of targeted therapy, the short-term curative effects of the two groups were evaluated, the occurrence of adverse reactions in the two groups were counted, the levels of serum tumor markers (carcinoembryonic antigen, carbohydrate antigen 19-9, and cytokeratin 19 fragment antigen 21-1) were detected at the time of enrollment and four months after targeted therapy, and the two-year survival rate was followed up.
The objective remission rate in the combined therapy group was 82.00%, which was significantly higher than 58.00% in the targeted therapy group (P<0.05). The adverse reactions such as rash, nausea and vomiting, fatigue, bone marrow suppression, diarrhea, liver and kidney injury in the two groups were all in the grade Ⅰ to Ⅲ, which were tolerated by the patients. There was no significant difference in the grade of adverse reactions between the two groups (P>0.05). After four months of targeted therapy, the levels of serum tumor markers in the two groups were significantly lower than those in the same group when joining the group (P<0.05), and the combined therapy group were significantly lower than those in the targeted therapy group in the same period (P<0.05). The two-year survival rate of the combined therapy group was 38.00%, which was significantly higher than that in the targeted therapy group (20.00%)(P<0.05).
Icotinib hydrochloride combined with IMRT in the treatment of brain metastasis from EGFR mutation-positive lung adenocarcinoma can achieve better short-term and long-term effects, and the adverse reactions are mild and can tolerated by the patients.